Certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-11. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical measurement of NMN typically uses high-performance liquid chromatography with ultraviolet detection, often at a wavelength near 260 nanometers. Liquid chromatography coupled with tandem mass spectrometry provides greater sensitivity and specificity, especially for biological samples. Nuclear magnetic resonance spectroscopy can confirm structure and detect certain impurities. Purity values reported by suppliers depend on the analytical method, calibration standards, and whether related compounds such as nicotinamide or NAD+ are included in the calculation. Independent verification is useful because supplement labels may not fully describe the tested material.
Regulatory treatment of NMN differs by country and has changed over time. In the United States, the Food and Drug Administration has stated that NMN is excluded from the definition of a dietary supplement because it was investigated as a drug before being marketed as a supplement; enforcement and legal interpretation continue to evolve. In the European Union, NMN may require authorization as a novel food before sale. In Japan, NMN has been marketed in some food products, while it is not approved as a therapeutic drug in major markets. These categories affect labeling, permitted claims, and quality oversight.
Solid NMN is generally handled as a moisture-sensitive and light-sensitive material. Suppliers commonly recommend storage at minus 20 degrees Celsius in a sealed, desiccated container, protected from light. Aqueous solutions are less stable than the solid and may degrade faster at elevated temperatures or extreme pH values. Because NMN contains a phosphate ester and a glycosidic bond, hydrolysis and other degradation pathways are plausible under unfavorable conditions. Stability data from independent laboratories remain limited, so handling recommendations often reflect supplier practice rather than published consensus.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Solid form; desiccated and protected from light |
| Solubility class | Freely soluble in water | Polar compound; solubility depends on temperature and pH |
| Common analytical method | HPLC-UV | Often confirmed with LC-MS/MS for identity and purity |
| Purity assessment | 95% or higher typical research grade | Values vary by supplier and analytical method |
| Regulatory status | Varies by country | Not approved as a drug; US FDA has stated exclusion from dietary supplement definition |
Quality control for NMN focuses on identity, purity, residual solvents, heavy metals, and microbial limits. Because the molecule can absorb water, moisture content and packaging are relevant to shelf life. Suppliers may provide certificates of analysis, but independent verification is often needed for research or commercial use. The long-term stability of different crystal forms, salt forms, and formulations is not fully characterized in the public literature. Some degradation products and their effects on product performance remain open questions.
As a commercial ingredient, nicotinamide mononucleotide is commonly supplied as a powder or capsule. Its stability depends on temperature, moisture, pH, and light exposure. Hydrolytic and thermal degradation can increase over time, so manufacturers and laboratories often store material cold and dry. Purity is typically assessed with chromatographic methods, and identity can be confirmed by mass spectrometry. Published stability data for specific finished products remain limited. More data would help define shelf life under real-world conditions.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
Quality control for NMN materials typically includes appearance, assay, impurity profile, residual solvents, heavy metals, and microbial limits. A certificate of analysis summarizes specified tests, but the underlying methods and laboratory accreditation matter. Regulatory treatment varies by country; NMN is sold as a dietary supplement in some markets, while other jurisdictions restrict its use in foods or classify it differently. Independent verification can reduce risks of mislabeling or substitution. Questions remain about how product purity, storage history, and formulation affect delivered dose in humans.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
To overcome this, GLP-1 receptor agonists and DPP-4 inhibitors have been developed to increase GLP-1 activity. As opposed to common treatment agents such as insulin and sulphonylureas, GLP-1-based treatment has been associated with weight loss and a lower risk of hypoglycemia, two important considerations for patients with type 2 diabetes.
In 2024, Dalman and colleagues described the remains of a tyrannosaur discovered in 1983 in the Campanian-early Maastrichtian Hall Lake Formation in New Mexico. Reposited at the New Mexico Museum of Natural History and Science, the fossil material (NMMNH P-3698) consists of the right postorbital, right squamosal, left palatine, and an incomplete maxilla from the skull, the left dentary, right splenial, right prearticular, right angular and right articular from the lower jaws, isolated teeth, and chevrons. Some of the bones were briefly mentioned in 1984 as belonging to T. rex, and described in 1986. Lehman and Carpenter (1990) suggested that NMMNH P-3698 belonged to a new tyrannosaurid genus, while Carr and Williamson (2000) disagreed with their claim. Sullivan and Lucas (2015) argued that there is little evidence to support NMMNH P-3698 as a specimen of Tyrannosaurus rex, so they tentatively classified it as cf. Tyrannosaurus sp.; they also considered that the McRae tyrannosaur lived before the Lancian (before 67 million years ago) based on its probable association with the Alamosaurus fossil.
Bone fractures occur because the stress state within collagen fibrils is altered at the locations of mutations, where locally larger shear forces lead to rapid failure of fibrils even at moderate loads because the homogeneous stress state normally found in healthy collagen fibrils is lost. OI is therefore a multi-scale phenomenon, where defects at the smallest levels of tissues (genetic, nano, micro) domino to affect the macro level of tissues.
In particle physics and nuclear physics, the branching fraction (or branching ratio) for a decay is the fraction of particles which decay by an individual decay mode or with respect to the total number of particles which decay. It applies to either the radioactive decay of atoms or the decay of elementary particles. It is equal to the ratio of the partial decay constant of the decay mode to the overall decay constant. Sometimes a partial half-life is given, but this term is misleading; due to competing modes, it is not true that half of the particles will decay through a particular decay mode after its partial half-life. The partial half-life is merely an alternate way to specify the partial decay constant λ, the two being related through:
Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It may be used by mouth and by injection into a muscle (IM). The intramuscular form may be used for acute agitation in people with schizophrenia. Common side effects include tremors, tics, dizziness, dry mouth, restlessness, nausea, and mild sedation. Although it can also cause weight gain, the risk is much lower than for other atypical antipsychotics. How it works is not entirely clear but is believed to involve effects on serotonin and dopamine in the brain. Ziprasidone was approved for medical use in the United States in 2001. The pills are made up of the hydrochloride salt, ziprasidone hydrochloride. The intramuscular form is the mesylate, ziprasidone mesylate trihydrate, and is provided as a lyophilized powder. In 2020, it was the 282nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Sources: en.wikipedia.org
=== Russian involvement === It was noted by Newsweek in July 2024 that the Houthis were in possession of Russian-made P-800 Oniks missiles, and that the transfer had likely occurred via Syria and Iran. In July 2024, The Wall Street Journal reported that US officials saw increasing indications that Russia was considering arming the Houthis with advanced anti-ship missiles via Iranian smuggling routes in response to US support for Ukraine during Russia's invasion. However, it did not follow through due to pushback by the US and Saudi Arabia. In August 2024, Middle East Eye, citing a US official, reported that personnel of Russia's GRU were stationed in Houthi-controlled parts of Yemen to assist the militia's attacks on merchant ships. In October, The Wall Street Journal reported that Russia was supplying the Houthis with geospatial intelligence to target Western ships.
Ideas of Sir Ronald A. Fisher still play a role in clinical trials. While working for the Rothamsted experimental station in the field of agriculture, Fisher developed his Principles of experimental design in the 1920s as an accurate methodology for the proper design of experiments. Among his major ideas include the importance of randomization—the random assignment of individual elements (eg crops or patients) to different groups for the experiment; replication—to reduce uncertainty, measurements should be repeated and experiments replicated to identify sources of variation; blocking—to arrange experimental units into groups of units that are similar to each other, and thus reducing irrelevant sources of variation; use of factorial experiments—efficient at evaluating the effects and possible interactions of several independent factors. Of these, blocking and factorial design are seldom applied in clinical trials, because the experimental units are human subjects and there is typically only one independent intervention: the treatment. The British Medical Research Council officially recognized the importance of clinical trials from the 1930s. The council established the Therapeutic Trials Committee to advise and assist in the arrangement of properly controlled clinical trials on new products that seem likely on experimental grounds to have value in the treatment of disease. The first randomised curative trial was carried out at the MRC Tuberculosis Research Unit by Sir Geoffrey Marshall (1887–1982).
=== Sequence similarity === EC categories do not reflect sequence similarity. For instance, two ligases of the same EC number that catalyze exactly the same reaction can have completely different sequences. Independent of their function, enzymes, like any other proteins, have been classified by their sequence similarity into numerous families. These families have been documented in dozens of different protein and protein family databases such as Pfam.
Alongside his collaborators, Karl Piez and George Martin at the National Institute of Health, Gross discovered that collagen was composed of three polypeptide chains. These experiments opened up the field of collagen biology. In the early 1960s, Gross began searching for mechanisms whereby collagen fibers are degraded during tissue remodeling alongside Belgian postdoctoral fellow Charles Lapiere. Gross reasoned that collagenolytic enzymes, which previously had been identified only in bacteria, could be made only when and where they were needed. They looked for collagenase in the medium from tissue implants in culture. Together, they found the enzyme and characterized its mechanism of action and its unique cleavage site. With such colleagues as Martin Tanzer, Utaka Nagai, Andrew Kang, and others, Gross continued studies of mechanisms of collagenolysis, lathyrism, and wound healing. In 1969, Gross was promoted to Professor of Medicine at Harvard Medical School and named Biologist at the Massachusetts General Hospital. Scientists from all over the world worked in Gross's Developmental Biology Laboratory in the Department of Medicine at the Massachusetts General Hospital. Gross continued to make important observations on collagen structure, mechanisms of fibrillogenesis, the role of hyaluronic acid and hyaluronidase in wound healing, embryogenesis and limb regeneration, the origin of corneal ulcers, and control of collagenase production. Gross died at age 96 in Waban, Massachusetts of natural causes
== Clinical significance == Deregulation of the expression and function of ITGA2 has been shown to be involved in a number of pathological states such as cancer, fibrosis, and cardiovascular disease. As integrin α2β1 mediates cellular interactions with the extracellular matrix, any changes in its expression may affect cellular activity and disease development. One of the most studied functions of the α2β1 integrin is connected with cancer biology. It has been shown that dysregulated expression of ITGA2 occurs in a number of cancers including breast, prostate, pancreatic, lung, colorectal, and gastric cancer. In most types of tumors, elevated expression of α2β1 increases the capacity of cancer cells to bind with collagen-rich extracellular matrices and migrate to other tissues. However, there is evidence that in some cancers the function of α2β1 might be involved in tumor suppression due to the maintenance of normal cell-matrix interactions. Further, changes in the level of activity of α2β1 have been associated with development of fibrosis. This condition is known to be associated with the deposition of excess quantities of extracellular matrix components, mostly collagens. Therefore, the activation of the signaling pathways mediated by the α2β1 integrin is likely to play a role in matrix remodeling in conditions such as pulmonary, hepatic, renal, and cardiac fibrosis. As a result, scientists have hypothesized that it might be possible to regulate the activity of α2β1 to prevent collagen accumulation.
Sources: en.wikipedia.org
252Cf(12C,αxn)260−xNo (x=3?) This reaction was studied at the LBNL in 1961 as part of their search for element 104. They detected 8.2 MeV alpha particles with a half-life of 15 s. This activity was assigned to a Z=102 isotope. Later work suggests an assignment to 257No, resulting most likely from the α3n channel with the 252Cf component of the californium target.
"Neats" hope that intelligent behaviour is described using simple, elegant principles (such as logic or optimisation). "Scruffies" expect that it necessarily requires solving a large number of unrelated problems. Neats defend their programs with theoretical rigour, scruffies rely mainly on incremental testing to see if they work. This issue was actively discussed in the 1970s and 1980s. The rise of deep learning may represent a shift toward the scruffies.
== Contributions == While still a student, Knudsen worked at Novo Nordisk, initially working on laundry detergent enzymes. Alongside fellow student Shamkant Patkar, she discovered an enzyme capable of removing microscopic strands of cotton that pill up on clothing from repeated wear. After this project, Knudsen joined full-time as part of a research group at Novo Nordisk that aimed to identify new treatments for diabetes, by developing small molecule drugs targeting specific metabolic pathways. One project revolved around glucagon-like peptide-1 (GLP-1), a hormone that stimulates the production of insulin but has a short half-life of minutes in the body. GLP-1 had been previously identified by researchers such as Jens Juul Holst in Denmark, who joined Novo Nordisk as a consultant, and Joel Habener, Daniel J. Drucker, and Svetlana Mojsov at Massachusetts General Hospital. Knudsen's team screened numerous chemical compounds to identify whether they could bind to the GLP-1 receptor sufficiently to stimulate insulin secretion. Eventually, they developed a new compound called liraglutide, which is an agonist for the GLP-1 receptor. It is a chemical analogue of GLP-1, with a fatty acid and spacer attached. These modifications increased its ability to dissolve in water and bind to albumin, which increase its bioavailability—its lifetime in the bloodstream, and so the duration of its action in the body. Liraglutide was approved as a treatment for diabetes under the brand name Victoza in the United States in 2010.
== Metabolism == In mammals, 1,6-dichloro-1,6-dideoxyfructose is metabolized in the liver and erythrocytes by a reaction with glutathione that replaces one of the chlorine atoms, forming 6-chlorofructos-1-yl glutathione (or chlorofructosyl glutathione).
==== Buccal ==== Buccally administered medication is achieved by placing the drug between gums and the inner lining of the cheek. In comparison with sublingual tissue, buccal tissue is less permeable resulting in slower absorption.
Sources: en.wikipedia.org
Solid NMN is commonly stored frozen at about minus 20 degrees Celsius, sealed against moisture, and protected from light. Solutions are typically prepared fresh because they can degrade more quickly. Specific storage conditions can vary by supplier and intended use.
Common methods include high-performance liquid chromatography with ultraviolet detection and liquid chromatography with mass spectrometry. Nuclear magnetic resonance spectroscopy can provide structural confirmation. Reported purity depends on the method and the reference standards used.
NMN is not approved as a therapeutic drug in the United States, European Union, or Japan. Its legal status as a supplement or food ingredient varies by jurisdiction. In the United States, the FDA has stated that NMN is excluded from the dietary supplement definition, though enforcement has been debated.
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.